Company intelligence / Profile preview

GIPIT

Ownership: Private
Development stage: Other

Overview

GIPIT is an early-stage biotechnology company focused on developing next-generation peptide therapeutics targeting the gastric inhibitory polypeptide (GIP) pathway. The company leverages a proprietary engineering platform to design GIP receptor (GIPR) agonists and antagonists with optimized pharmacological profiles for the treatment of metabolic diseases. GIPIT's primary focus is on addressing obesity and type 2 diabetes by modulating GIP signaling, either as monotherapies or in combination with other incretin mimetics. The company aims to improve upon existing metabolic treatments by enhancing weight loss efficacy and glycemic control while minimizing side effects.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: PeptidesBiologic
Industry: Biotech

Beyond the preview

Go deeper on GIPIT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GIPIT.

Explore the full profile